ReviewPharmaceutics2018
Ophthalmic Drug Delivery Systems for Antibiotherapy-A Review.
Review in Pharmaceutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Advanced Ophthalmic Drug Delivery in Homocystinuria Type CblC: A Translational Review of Ophthalmic Pathologies and Therapeutic Opportunities.Pharmaceutics · 2026Review
- Evaluation of Propolis and Diclofenac Sodium Eye Drops for Animals: Physicochemical Properties and In Vitro Biological Activity.Gels (Basel, Switzerland) · 2026Article
- Effects of repeated culture in sub-inhibitory concentrations of ciprofloxacin on resistance and genetic characteristics of an ocular Pseudomonas aeruginosa isolate.World journal of microbiology & biotechnology · 2026Article
- Controlled Release of Thermosensitive Hydrogel Incorporating Betaxolol-Loaded Resin Microspheres for Glaucoma Therapy.AAPS PharmSciTech · 2026Article
- Development and kinetic evaluation of vitamin C-loaded contact lenses prepared by a simple soaking technique.Frontiers in medical technology · 2026Article
- Article
- Management of corneal injuries in spaceflight and recommendations for planetary missions.NPJ microgravity · 2025Article
- Envisioning the Future: Nanomicelles Revolutionizing Ocular Drug Delivery.Pharmaceutical nanotechnology · 2025Review
- Development of Gentamicin Bilosomes LadenAdvanced pharmaceutical bulletin · 2024Article
- Biodegradable microspheres come into sight: A promising biomaterial for delivering drug to the posterior segment of the eyeball.Materials today. Bio · 2024Review
- Article
- Recent updates on ocular disease management with ophthalmic ointments.Therapeutic delivery · 2024Review
- Nanotechnology-based ocular drug delivery systems: recent advances and future prospects.Journal of nanobiotechnology · 2023Review
- Innovative Strategies for Drug Delivery to the Ocular Posterior Segment.Pharmaceutics · 2023Review
- Recent Progress of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Ocular Drug Delivery Platforms.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Review
- Biopolymers in Mucoadhesive Eye Drops for Treatment of Dry Eye and Allergic Conditions: Application and Perspectives.Pharmaceutics · 2023Review
- Review
- Protein and polypeptide mediated delivery to the eye.Advanced drug delivery reviews · 2022Review
- Degradable and Non-Degradable Chondroitin Sulfate Particles with the Controlled Antibiotic Release for Bacterial Infections.Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The last fifty years, ophthalmic drug delivery research has made much progress, challenging scientists about the advantages and limitations of this drug delivery approach. Topical eye drops are the most commonly used formulation in ocular drug delivery. Despite the good tolerance for patients, this topical administration is only focus on the anterior ocular diseases and had a high precorneal loss of drugs due to the tears production and ocular barriers. Antibiotics are popularly used in solution or in ointment for the ophthalmic route. However, their local bioavailability needs to be improved in order to decrease the frequency of administrations and the side effects and to increase their therapeutic efficiency. For this purpose, sustained release forms for ophthalmic delivery of antibiotics were developed. This review briefly describes the ocular administration with the ocular barriers and the currently topical forms. It focuses on experimental results to bypass the limitations of ocular antibiotic delivery with new ocular technology as colloidal and in situ gelling systems or with the improvement of existing forms as implants and contact lenses. Nanotechnology is presently a promising drug delivery way to provide protection of antibiotics and improve pathway through ocular barriers and deliver drugs to specific target sites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.